Stoyanova Zdravka, Temelkova Katya, Ganeva Margarita, Vasilev Teodor, Dasheva-Dimitrova Anna, Kibarova-Hristova Desislava, Stefanov Stefan
Pediatric Rheumatology Department, University Children's Hospital "Ivan Mitev", 11 "Akademik Ivan Evstratiev Geshov" Blvd., 1606 Sofia, Bulgaria.
Pediatrics Department, Faculty of Medicine, Medical University of Sofia, 15 "Akademik Ivan Evstratiev Geshov" Blvd., 1431 Sofia, Bulgaria.
Curr Issues Mol Biol. 2025 May 7;47(5):334. doi: 10.3390/cimb47050334.
Multisystem inflammatory syndrome in children (MIS-C) is a rare, delayed hyperinflammatory response, which occurs 2-6 weeks after SARS-CoV-2 infection. Main symptoms include fever, involvement of at least two organ systems, elevated inflammatory markers and evidence of infection with or exposure to SARS-CoV-2. While the prognosis is generally favorable, complications-such as myocardial dysfunction, coronary aneurysms, and coagulation disorders-can lead to severe outcomes, including death. Immunomodulatory and antithrombotic therapies are key components of treatment. We report a clinical case of a 3-year-old boy who developed MIS-C, initially presenting with fever, multiorgan involvement, and confirmed SARS-CoV-2 infection, along with a coinfection caused by group A β-hemolytic Streptococcus (GAS) isolated from throat culture. On the ninth day of illness, thrombosis of the right subclavian vein was detected. Subsequent genetic testing for thrombophilia revealed that the patient was a heterozygous carrier of , and . Thromboembolic events (TEs) are serious and potentially life-threatening complications of MIS-C. This case highlights the occurrence of TE in a 3-year-old boy, an age group younger than typically observed, emphasizing the need for heightened awareness, early detection, and prompt intervention. Additionally, it underscores the importance of careful monitoring of thrombotic risks in MIS-C patients, particularly those with underlying prothrombotic conditions, to prevent severe outcomes.
儿童多系统炎症综合征(MIS-C)是一种罕见的迟发性高炎症反应,发生在新型冠状病毒2(SARS-CoV-2)感染后2至6周。主要症状包括发热、至少两个器官系统受累、炎症标志物升高以及感染或接触SARS-CoV-2的证据。虽然总体预后良好,但诸如心肌功能障碍、冠状动脉瘤和凝血障碍等并发症可导致严重后果,包括死亡。免疫调节和抗血栓治疗是治疗的关键组成部分。我们报告了一例3岁男孩发生MIS-C的临床病例,最初表现为发热、多器官受累,并确诊感染SARS-CoV-2,同时从咽拭子培养中分离出A组β溶血性链球菌(GAS)引起的合并感染。在患病的第9天,检测到右锁骨下静脉血栓形成。随后的血栓形成倾向基因检测显示,该患者是 和 的杂合子携带者。血栓栓塞事件(TEs)是MIS-C严重且可能危及生命的并发症。该病例突出了TE在一名3岁男孩中的发生,该年龄组比通常观察到的年龄小,强调需要提高认识、早期检测和及时干预。此外,它强调了在MIS-C患者中,特别是那些有潜在血栓形成倾向的患者,仔细监测血栓形成风险以预防严重后果的重要性。